LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) announces today the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.
